Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover to Assess the Dose Responsiveness of Exhaled Nitric Oxide to Fluticasone propionate/salmeterol marketed as Advair® Diskus® in Asthmatic Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society